FDA Approves Sorilux for Adolescent Plaque Psoriasis
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
A review of a decade of data highlights infection risks, including nontuberculous mycobacteria, among patients seeking surgery abroad and across state lines.